Zealand Pharma — Maj 2022
-
Enig Exitnu og I Zealand har man en CEO der solgte sine aktier i det sene 2021
-
Enig Exitnu. Men det sender altid nogle signaler til markedet, såvel når CEO køber aktier, der kan tolkes positivt af positivt af markedet. Et salg i kurs 206 i september 2021, kan Hr. Steensberg da ikke være utilfreds med
-
+8% smuk begyndelse på en vending,,
-
Deal includes $10 million USD upfront payment to Zealand and sales-based milestones
Certain inventory related to V-Go
and employees also included under the terms of the deal
Agreement is part of Zealand’s refocused strategy to seek partners for commercial and late-stage assets while prioritizing research and development -
du er så hurtig - tak
-
“This transaction is an important step forward in executing on the strategic refocusing we outlined at the end of March, as we find partners for our commercial and late-stage assets and prioritize the research and development of innovative new peptide therapeutics,” said Adam Steensberg, MD, Chief Executive Officer of Zealand Pharma. “We believe MannKind is the right partner to fully leverage the value of V-Go and ensure its continued availability for the patients and prescribers who need it.”
-
13%!
-
ledelsen er så hurtige til at eksekvere på ny strategi - god timing med Q
&A -
Zealand Pharma sælger V-Go-insulinleveringsenhed for 10 mio. dollar https://www.proinvestor.com/investornyt/825478/zealand-pharma-saelger-v-go-insulinleveringsenhed-for-10-mio-dollar
-
Biotek-boss efter frasalg: “I træskolængder får vi formentlig det samme ind som vi har givet”
Salget af produktet V-Go for 10 mio. dollar up-front er nogenlunde samme pris, som selskabet betalte i 2020
https://borsen.dk/nyheder/virksomheder/zealand-pharma-foran-med-oprydningsplan-efter-salg
-
Zealand Pharma banker op på børsen efter frasalg af insulinpumpe
Zealand Pharma henter lidt tilbage af det tabte på aktiemarkedet, efter selskabet har haft sucess med at sikre sig et frasalg af insulinpumpen V-Go.
-
Flere spørgsmål til Q&A er meget velkommen.
-
clinicaltrials.gov - May 18, 2022 Drug: Dasiglucagon Phase 3: "A Research Study to Investigate the Safety and Effect of Dasiglucagon as a Hypoglycemia Rescue Therapy and How it Works in the Body of Children Under 6 Years of Age With Type 1 Diabetes" (Not yet recruiting).
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind